End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line...Read more
Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological &...Read more
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of...Read more
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reactions1-5 Approval builds on previously reported Phase 3 MARIPOSA data showing unmatched overall...Read more
Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing significantly lower rate of annualized asthma exacerbations in patients receiving depemokimab versus...Read more
Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel...Read more
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| United Therapeutics | 10.94 2.19 | $510.94 |
| argenx | 10.63 1.25 | $862.05 |
| Proces Pharmaceuticals | 6.77 5,636.27 | $6.90 |
| Belite Bio | 5.08 3.41 | $154.21 |
| Bolt Biotherapeutics | 4.89 873.21 | $5.45 |
| DBV Technologies | 4.57 25.42 | $22.55 |
| Movano Health | 4.03 129.58 | $7.14 |
| Regeneron Pharmaceuticals | 3.43 0.46 | $749.79 |
| Quoin Pharmaceuticals | 2.88 24.57 | $14.60 |
| Kodiak Sciences | 2.84 11.77 | $26.97 |
| Inspire Medical Systems | 2.76 2.39 | $118.27 |
| AbbVie | 2.69 1.20 | $226.36 |
| West Pharmaceutical | 2.69 1.01 | $269.13 |
| Gilead Sciences | 2.58 2.17 | $121.36 |
| IDEXX Laboratories | 2.42 0.35 | $695.60 |
| Intuitive | 2.28 0.41 | $556.86 |
| Univerl Health Services | 2.26 1.02 | $224.90 |
| Humana | 2.12 0.82 | $260.28 |
| Company | Volume | Last Trade |
|---|---|---|
| VYNE Therapeutics | 925,626,759 | $0.64 |
| WORK Medical Technology | 211,906,951 | $0.06 |
| Vistagen | 164,656,787 | $0.87 |
| Aditxt | 124,485,058 | $1.72 |
| HeartBeam | 88,134,311 | $3.08 |
| Recursion | 68,917,962 | $4.69 |
| Applied Therapeutics | 59,338,473 | $0.12 |
| Pfizer | 57,712,662 | $25.07 |
| Kyverna Therapeutics | 53,755,389 | $7.04 |
| Immunome | 53,542,954 | $19.94 |
| Tenaya Therapeutics | 40,295,353 | $0.68 |
| Rezolute | 31,963,314 | $2.01 |
| Milestone Pharmaceuticals | 31,767,959 | $2.15 |
| Incannex Healthcare | 28,677,156 | $0.41 |
| Proces Pharmaceuticals | 23,378,184 | $6.90 |
| Adicet Bio | 22,309,395 | $0.47 |
| Geron | 22,205,949 | $1.40 |
| ImmunityBio | 21,626,093 | $2.11 |
| Century Therapeutics | 18,047,979 | $0.67 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
